Merck & Co’s immuno-oncology drug Keytruda (pembrolizumab) is projected to be the best-selling drug by annual revenue in 2023, earning $22.2 billion by 2025, according to new research by GlobalData.

NerdWallet's list of the best savings accounts. Many, or all, of the products featured on this page are from our advertising partners who compensate us when you take certain actions on our website ...